{"id":"W2907212631","doi":"10.1016/j.cllc.2018.12.022","title":"Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol","year":2019,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"Janssen Pharmaceuticals; Merck Sharp and Dohme; Genentech; Takeda Pharmaceutical Company; AbbVie; Celgene; Medtronic; Novartis; Sanofi; Merck; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Roche; Astellas Pharma US; Boehringer Ingelheim; Amgen; Pfizer","keywords":"Medicine; Afatinib; Pembrolizumab; Squamous-cell carcinoma of the lung; Lung; Lung cancer; Oncology; Internal medicine; Basal cell; Cancer; Immunotherapy; Gefitinib; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001646551,0.0003384619,0.000825073,0.00004420905,0.0001301047,0.00001428629,0.0002225004,0.00006606639,0.0001164467],"category_scores_gemma":[0.00004685255,0.0001438768,0.0002663005,0.0002753767,0.0002422821,0.00008206015,0.0000440639,0.0001373408,0.000001900333],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003752884,"about_ca_system_score_gemma":0.001155962,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001523529,"about_ca_topic_score_gemma":0.0001531561,"domain_scores_codex":[0.9975958,0.0001429761,0.0008571271,0.0005258062,0.0005363788,0.0003419477],"domain_scores_gemma":[0.997102,0.0005681659,0.0007196841,0.0009334812,0.0005460144,0.0001306048],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01101763,0.005431265,0.9762883,0.0008090842,0.0007259249,0.000004249917,0.00113594,0.0008202141,0.000007617109,0.00001780836,0.0005195519,0.003222426],"study_design_scores_gemma":[0.08088655,0.02442735,0.8857549,0.0003706692,0.004399075,0.000001783552,0.0005644635,0.001467617,0.0003448449,0.00001072853,0.001530057,0.0002419697],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.836602,0.0002691183,0.0001220278,0.0001981955,0.0002033001,0.1617771,0.0001802217,0.00001704885,0.0006309197],"genre_scores_gemma":[0.9177352,0.000005923297,0.0003911135,0.0001445196,0.00007493017,0.07983641,0.00002422663,0.00006067142,0.001727067],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09053339,"threshold_uncertainty_score":0.5867125,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01969337257832399,"score_gpt":0.3966256232321059,"score_spread":0.3769322506537819,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}